P. Firby

579 citations
10 papers · 494 indexed · h-index 8

P. Firby

10 papers receiving 473 citations

Peers

P. Firby
Comparison fields: 5 of 71
  • Oncology 266
  • Radiology, Nuclear Medicine and Imaging 132
  • Cancer Research 48
  • Physiology 14
  • Biotechnology 25
Replace G. R. Boniface with:
G. R. Boniface Australia
Joanna Regis United States
Sikic Bi United States
Hiromi Tanii Japan
Artemios B. Vassos United States
Max Sauter Germany
Roger Y. Tsang Canada
T. L. Loo United States
W J van der Vijgh Netherlands
Yuan‐Chin Tsai United States
P. Firby relative to G. R. Boniface Australia G. R. Boniface's profile →
Citations per field
00.5×
G. R. Boniface · 1×
Citations per year

Countries citing papers authored by P. Firby

Since Specialization
Citations

This map shows the geographic impact of P. Firby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Firby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Firby more than expected).

Fields of papers citing papers by P. Firby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Firby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Firby. The network helps show where P. Firby may publish in the future.

Co-authorship network

The 25 scholars most cited alongside P. Firby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P. Firby Line = papers co-authored together P. Firby links everyone, so they are left out of the graph.

All Works

10 of 10 papers shown
#Work
1 200378
2
Pharmacological determinants of 9-aminocamptothecin cytotoxicity.
20019
3 200035
4
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
2000123
5 199825
6
Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells.
1996105
7 1995101
8 19931
9 199214
10 19893

About P. Firby

P. Firby is a scholar working on Toxicology, Physiology and Oncology, having authored 10 papers that have together received 494 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (3 papers), Cancer therapeutics and mechanisms (2 papers), Neutropenia and Cancer Infections (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers), RNA modifications and cancer (1 paper), Microbial Metabolism and Applications (1 paper), Neuroendocrine Tumor Research Advances (1 paper) and Analytical Chemistry and Chromatography (1 paper). The work is most often cited by research in Oncology (266 citations), Radiology, Nuclear Medicine and Imaging (132 citations) and Cancer Research (48 citations). P. Firby has collaborated with scholars based in Canada. Frequent co-authors include Malcolm J. Moore, IZZIE BOXEN, David W. Hedley, Brian W. Berry, James R. Ballinger, Hong Hua, Niklas Hartmann, Lillian L. Siu, Nancy Wainman and Karen A. Gelmon. Their work appears in journals such as Journal of Clinical Oncology, Canadian Journal of Physiology and Pharmacology and Therapeutic Drug Monitoring.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026